Background Transfusion thresholds for acute upper gastrointestinal bleeding are controversial. So far, only three small, underpowered studies and one single-centre trial have been done. Findings from the single-centre trial showed reduced mortality with restrictive red blood cell (RBC) transfusion. We aimed to assess whether a multicentre, cluster randomised trial is a feasible method to substantiate or refute this fi nding.
Introduction
Acute upper gastrointestinal bleeding accounts for 70 000 admissions every year to UK hospitals 1 and for 11% of all red blood cells (RBCs) transfused in England. 2 Despite being the most common single indication for RBC transfusion, the optimum threshold for transfusion is uncertain. 3 Findings from randomised trials in other cohorts such as those who have had cardiac surgery, 4 are in critical care, 5 or have had hip surgery 6 have shown that thresholds for transfusion can be safely lowered without adversely aff ecting outcomes.
Whether a restrictive approach to transfusion can safely be extrapolated to elderly patients with acute bleeding or cardiovascular disease is unclear, 7-10 which is particularly relevant to patients with acute upper gastrointestinal bleeding, in whom the burden of comorbidity is often high. 3, 11 Findings from cohort studies suggest associations between RBC transfusion after acute upper gastrointestinal bleeding and adverse clinical outcomes. 12, 13 Investigators of a single-centre, randomised controlled trial 14 that took place for 6 years in a specialist gastrointestinal bleeding unit in Barcelona, Spain, reported reduced mortality and rebleeding with implementation of restrictive transfusion for acute upper gastrointestinal bleeding. However, these results are unlikely to be generalisable to routine clinical practice because of exclusion of patients with major cardiovascular comorbidity, stringent processes of care, and diff ering case mix. 3 A large, pragmatic, multicentre trial is essential to either substantiate or refute these fi ndings before clinical practice guidelines are changed worldwide to recommend restrictive transfusion for all patients with acute upper gastrointestinal bleeding. Because acute upper gastrointestinal bleeding is a medical emergency that can need early transfusion and many care providers, a trial that needs adherence to transfusion strategies across many centres would be challenging to do.
In the Transfusion in Gastrointestinal Bleeding Trial (TRIGGER), we aimed to assess whether a restrictive or liberal RBC transfusion policy for acute upper gastrointestinal bleeding in routine clinical practice is feasible and safe to implement through cluster randomisation, and did an exploratory analysis of the major clinical eff ects, enrolling all new adult admissions, irrespective of their comorbidity (except for exsanguinating haemorrhage) or age.
Methods

Study design and patients
We did this pragmatic, multicentre, open-label, cluster randomised feasibility trial of a restrictive versus liberal RBC transfusion policy in adults with acute upper gastrointestinal bleeding in the UK to inform the feasibility and design of a phase 3 trial. Because of the need for immediate implementation of an RBC transfusion policy from fi rst presentation until discharge, across several specialty groups in diff erent clinical areas of a hospital, we chose a cluster design to simplify intervention delivery and reduce contamination between policies. We deemed a feasibility trial essential to establish whether clinician behaviour could be changed on a hospital-wide scale and to assess potential for selection bias or outcome-reporting bias because of the open-label nature of the study. A rationale and methodology study has been published, 15 and the full protocol is available online.
Hospitals were eligible if they had more than 20 acute upper gastrointestinal bleeding admissions monthly, more than 400 adult beds, endoscopy available 24 h a day, onsite access to intensive care and surgery, and staff willing to be randomly allocated to and implement a transfusion policy for all new acute upper gastrointestinal bleeding admissions. Patients were eligible if they presented with new acute upper gastrointestinal bleeding (defi ned by haematemesis or melaena) and were aged 18 years or older; the only exclusion criterion was exsanguinating haemorrhage, for which we provided objective guidance criteria (appendix p 1). We sought written informed consent from individual patients or their representatives for use of routine hospital records and telephone follow-up at day 28. Ethics approval was granted in England (National Research Ethics Service Committee South Central-Oxford C; reference 12/ SC/0062) and Scotland (Scotland A Research Ethics Committee; reference 12/SS/0023).
Randomisation and masking
We randomly allocated (using a computer-generated randomisation sequence) centres to a transfusion policy using a random permuted block of six (three hospitals per policy), without stratifi cation or matching (randomisation done by BCK). We identifi ed patients from emergency departments and acute admissions units. All clinicians, patients, and outcome assessors were unmasked to treatment allocation.
Procedures
For the restrictive policy, patients were eligible for RBC transfusion when their haemoglobin concentration fell below 80 g/L, with a post-transfusion target of 81-100 g/L.
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Medicine For the liberal policy, patients were eligible when their haemoglobin concentration fell below 100 g/L, with a post-transfusion target of 101-120 g/L. These thresholds were informed by present UK transfusion practice. 15 The number of RBC units transfused and the timing of repeat haemoglobin concentration measurements was per clinician discretion. All clinicians could deviate from the policy, but were asked to document the reason. In keeping with the pragmatic design no other aspects of care were protocol driven, although clinicians were encouraged to follow evidence-based guidelines. 16, 17 A lead clinician championed the study at each site, supported by a coinvestigator from an allied acute specialty. We used a multifaceted approach to implement the policy, including the daily presence of a research nurse in acute areas, regular attendance by a member of the trial team at medical and nursing handovers in acute areas to reinforce the policy, departmental and grand round presentations, posters, regular email reminders, and a fl agging system in transfusion laboratories to remind doctors and transfusion laboratory scientifi c staff of the policy whenever a transfusion request for acute upper gastrointestinal bleeding occurred.
Outcomes
We collected both feasibility outcome measures and exploratory clinical outcome measures, listed in the study protocol. Feasibility outcomes were recruitment rate, adherence to transfusion policy (overall, per patient, and per haemoglobin count), diff erence in haemoglobin concen tration between groups, RBC exposure, evidence of selection bias, and information to guide the design and economic evaluation of the phase 3 trial. We measured haemoglobin concentrations (during the fi rst 7 days, the entire follow-up, and before discharge), the proportion of patients receiving at least one RBC transfusion, and the number of units transfused. Clinical outcomes included further bleeding, thromboembolic and ischaemic events, and number of infections (inhospital and day 28, with day 28 being the main analysis timepoint). We also assessed mortality, serious adverse events, and health-related quality of life (with Euroqol EQ-5D questionnaire) at day 28, and need for therapeutic intervention at index endoscopy, need for surgery or radiological intervention to control bleeding, and transfusion reactions.
Statistical analysis
On the basis of our predicted sample size of 849 patients, we estimated the precision with which we would be able to detect a diff erence in the mean Rockall 18 score between treatment policies, which might show selection bias. With a two-sided signifi cance level of 5%, an intracluster correlation coeffi cient of 0·033, and an SD of 1·84, 849 patients would provide 92% power to detect a mean diff erence of one point. 15 
Liberal policy (n=533)
Restrictive policy (n=403)
Baseline characteristics
Male 322 (60%) 244 (61%)
Blatchford score † 6 (2-10) 6 (1-9) Data are n (%), mean (SD), or median (IQR). *Data missing for one patient in the liberal policy. †Data missing for one patient in the liberal policy and six in the restrictive policy. ‡Data missing for two patients in the liberal policy. §Data missing for two patients in the liberal policy and one in the restrictive policy. ¶Data missing for one patient in the restrictive policy. ||Data missing for one patient in the liberal policy. **Data missing for two patients in the liberal policy and nine in the restrictive policy. † †Data missing for 53 patients in the liberal policy and 37 in the restrictive policy. ‡ ‡Data missing for 24 patients in the liberal policy and 11 in the restrictive policy. § §Data missing for 24 patients in the liberal policy and eight in the restrictive policy. ¶ ¶Data missing for nine patients in the liberal policy and one in the restrictive policy. ||||Endoscopy not performed for 146 patients in the liberal policy and 117 in the restrictive policy. The statistical analysis plan was published before database lock. 19 All analyses were predefi ned unless otherwise stated. We did analyses on all enrolled patients for whom an outcome was available. We also did analyses on all enrolled patients with a haemoglobin concentration of less than 120 g/L during follow-up because this group was expected to be most likely to receive a transfusion and be aff ected by the treatment policy.
Signs and symptoms
We analysed feasibility and clinical outcomes using cluster-level summaries, giving equal weight to each cluster. 20, 21 We presented results as a diff erence in means for continuous outcomes, and a diff erence in proportions for binary outcomes. Prespecifi ed subgroup analyses and post-hoc analyses are listed in the appendix p 3.
We did all analyses with Stata/IC 12.1. This trial is registered, ISRCTN85757829 and NCT02105532.
Role of the funding source
The funder of the study had no role in study design, data collection, data analysis, data analysis, data interpretation, or writing of the report. The writing committee had full access to all the data in the study and had fi nal responsibility for the decision to submit to publication. BCK and CJD are statistical guarantors.
Results
Between Sept 3, 2012, and March 1, 2013, 1667 patients were admitted to the six university hospitals in the UK participating in the trial with acute upper gastrointestinal bleeding, of whom 1600 (96%) were eligible and 936 (59%) of whom we enrolled: 533 (57%) into the liberal RBC transfusion policy and 403 (43%) into the restrictive policy (fi gure 1). Recruitment rate was signifi cantly higher in the liberal policy than the restrictive policy (62% vs 55%; p=0·04). 3% were ineligible because of exsanguinating bleeding (liberal group 19 [2%] of 896; restrictive group 33 [4%] of 771; p=0·08). The commonest reason for nonenrolment was consent refusal for data collection and telephone follow-up, which occurred in 430 (27%) of the 1600 eligible patients. Data for further bleeding at day 28 were missing in 29 (3%) of 936 patients randomly allocated, who we excluded from analysis. Telephone contact at day 28 to administer an EQ-5D questionnaire was not possible in 136 (34%) of 403 participants in the restrictive policy and 296 (56%) of 533 in the liberal policy.
Baseline characteristics were similar in terms of Rockall and Blatchford risk scores, blood pressure, heart rate, and symptoms of bleeding (table 1, appendix p 2). Some baseline imbalances in comorbidities existed, with a greater proportion of patients in the liberal policy than the restrictive policy with liver disease, whereas more patients in the restrictive policy had respiratory disease or hypertension. Ischaemic heart disease was 
Data are mean (SD). similar between treatment groups. In the liberal policy, patients enrolled were older than those not enrolled compared with the restrictive policy, in which patients enrolled were younger than those not enrolled (table 2) . Overall adherence to the transfusion protocol (mean number of haemoglobin counts with no deviations, per patient) was signifi cantly higher in the restrictive policy (96%; SD 10) than the liberal policy (83%; SD 25; diff erence 14% [95% CI 7-21]; p=0·005), with a similar pattern noted in patients with a haemoglobin concentration of less than 120 g/L (restrictive policy 94% [SD 12] vs liberal policy 76% [27] ; diff erence 19% [95% CI [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] ; p=0·003) (table 3) . Adherence each month was consistent in the restrictive policy, but decreased over time in the liberal policy (fi gure 2). In the liberal policy, 675 (24%) of 2769 of all haemoglobin measurements led to a protocol deviation (672 no transfusion when haemoglobin concentration was less than 100 g/L; three transfusions when haemoglobin concentration was 100 g/L or higher), compared with 93 (5%) of 1754 in the restrictive group (67 no transfusion when haemoglobin concentration was less than 80 g/L; 26 transfusions when haemoglobin concentration was 80 g/L or higher). 247 (46%) of 533 patients allocated to the liberal policy were transfused compared with 133 (33%) of 403 patients allocated to the restrictive policy (diff erence -12%; 95% CI -35 to 11; p=0·23; table 3 ). The mean number of units transfused was lower in the restrictive policy than the liberal policy, although this diff erence was not signifi cant (restrictive policy 1·2 [SD 2·1]; liberal policy 1·9 [2·8]; diff erence -0·7 [95% CI -1·6 to 0·3]; p=0·12). In patients with a haemoglobin concentration of less than 120 g/L, concentration at hospital discharge was signifi cantly lower in the restrictive policy than in the liberal policy (restrictive policy 101 g/L [SD 13]; liberal policy 107 g/L [12] ; diff erence -7 g/L, 95% CI -14 to 0; p=0·05) (fi gure 3). In patients with a haemoglobin concentration of less than 100 g/L, mean concentration during the entire follow-up and at discharge was signifi cantly lower in the restrictive policy than the liberal policy (table 3) . We noted no signifi cant diff erences in clinical outcomes or mean EQ-5D scores between treatment groups (table 4).
Discussion
We report the fi rst multicentre randomised trial comparing transfusion strategies for acute upper gastrointestinal bleeding, gathering evidence for the feasibility of a phase 3 trial (panel). The pragmatic eligibility criteria meant that 96% of patients admitted to the six hospitals during the recruitment period were eligible, of whom almost 60% were enrolled. The cluster design was acceptable to clinicians, resulted in an effi cient recruitment rate, and enabled implementation of the transfusion policy hospital-wide, alongside routine clinical care. High adherence to both transfusion policies was achieved, resulting in a 13% absolute reduction in the proportion of patients transfused in the restrictive policy, reduction in the amount of blood transfused between treatment policies, and separation in haemoglobin concentration, although none of these between-group diff erences were signifi cant. The small, non-signifi cant reduction in mean number of RBC units transfused was in keeping with that reported in a meta-analysis of transfusion trigger trials. 26 Protocol adherence was better in the restrictive policy than the liberal policy-restrictive policy protocol adherence was consistent throughout the trial. In the liberal policy, most violations were due to RBCs not being administered below the threshold of 100 g/L. This greater adherence to the restrictive policy than the liberal policy could be due to clinician bias towards low transfusion thresholds for acute upper gastrointestinal bleeding, particularly for low-risk patients, extrapolated from evidence of the safety of restrictive transfusion in trials of critical care, 5 cardiac surgery, 4 and hip surgery. 10 Our liberal threshold of 100 g/L was informed by actual UK transfusion practice at the time the study was designed in 2009. Guidelines advocating restrictive transfusion for acute upper gastrointestinal bleeding are based on one trial done in an intensive care population 5 in which patients with acute bleeding were specifi cally excluded; transfusion requirements might reasonably be expected to diff er after acute bleeding because of rapid development of anaemia and haemodynamic compromise. For the phase 3 trial, we plan to lower the threshold for transfusion in the liberal group to take account of this changing practice and we would also exclude low-risk patients (with a Rockall score of 0) who are unlikely to be transfused. The greater protocol adherence in the restrictive than the liberal policy might also have been infl uenced by the Barcelona trial of transfusion strategies for gastrointestinal bleeding, 14 published during recruitment to TRIGGER. In this single-centre trial, improved survival and rebleeding rates were noted in patients transfused below a haemoglobin concentration of 70 g/L compared with those transfused below 90 g/L. Whether these results could be collected in other hospitals, particularly in the UK, is questionable on several grounds. First, a high proportion of the trial population had liver cirrhosis and variceal bleeding, and a treatment eff ect was only seen in patients for whom mechanisms of bleeding diff er and who account for only 10% of UK presentations with acute upper gastrointestinal bleeding. Second, the trial excluded patients with major comorbidities, including ischaemic heart disease, vascular disease, or stroke, which excludes almost 40% of all UK presentations with acute upper gastrointestinal bleeding, 27 representing the group at greatest potential of complications from acute anaemia. Third, processes of care are unlikely to be reproducible at other institutions, specifi cally delivery of therapeutic endoscopy to all patients within 6 h, which might aff ect transfusion use. Furthermore, single-centre trials tend to fi nd larger treatment eff ects than multicentre trials, 28 highlighting the risk of strong recommendations on the basis of a single-centre trial. 28, 29 Despite some baseline imbalances, participants in each policy had similar risk scores and haemodynamic status. Patients enrolled in the liberal policy were older than those not enrolled, whereas in the restrictive group, patients enrolled were younger than those not enrolled. These diff erences are probably chance imbalances due to the small number of clusters. For the main trial, about 30 clusters would need to be randomly allocated, which should achieve acceptable balance between treatment arms. Prespecifi ed covariate adjustment would account for any unexpected baseline imbalances in important prognostic factors. 30 Baseline imbalances could have been due to selection bias because of the open-label nature of the study. Prevention of selection bias will be important in the phase 3 trial. A potential solution would be to seek a consent waiver for anonymous data collection to allow routinely collected data to be summarised for all eligible participants.
TRIGGER was not a phase 3 trial, so its clinical outcomes should not be used to inform clinical practice directly. A key area of uncertainty in transfusion practice concerns safe transfusion thresholds in patients with ischaemic heart disease, 8, 10, 31 particularly relevant to acute upper gastrointestinal bleeding; 14% of patients with acute upper gastrointestinal bleeds have ischaemic heart disease. 11, 12 Findings from a pilot trial of transfusion strategies in patients with ischaemic heart disease 10 showed a 15% absolute increase in mortality in patients receiving transfusion at a threshold of haemoglobin concentration of 80 g/L compared with 100 g/L, a similar magnitude of excess mortality as that observed in TRIGGER (appendix, p 4), showing the need for further evidence before universal restrictive transfusion for acute upper gastrointestinal bleeding can be advocated.
This feasibility trial provides key learning points for design of the phase 3 trial. We plan to enrol the same patient population as in TRIGGER, using broad and inclusive eligibility criteria to promote effi cient recruitment and generalisability, although we would exclude the lowest-risk patients who are unlikely to be recipients of transfusion. For high-risk patients with ischaemic heart or cerebrovascular disease who might be particularly susceptible to adverse eff ects of anaemia, we would ask the Independent Data Monitoring Committee to monitor serious adverse events and provide Hospital discharge 21 (5%) 7 (3%) -3 (-9 to 2)
Surgical or radiological intervention
Hospital discharge 11 (3%) 10 (4%) 1 (-4 to 6)
Acute transfusion reactions ¶
Hospital discharge 9 (2%) 2 (1%) -2 (-4 to 1)
Therapeutic intervention
Hospital discharge 144 (38%) 81 (32%) -7 (-25 to 11)
Infections||
Hospital discharge 92 (24%) 67 (26%) 1 (-25 to 27)
Length of hospital stay (days)**
Hospital discharge 5 (3-9) 4 (3-7) -1 (-2 to 0) Data are n (%), median (IQR), mean (SD), or eff ect (95% CI). *Treatment eff ects are diff erences in means for continuous outcomes and diff erences in percentages for binary outcomes. †27 patients had missing data and were excluded from this analysis (19 liberal and eight restrictive). ‡One patient had missing data in the liberal group and was excluded from this analysis. §48 patients had missing data and were excluded from this analysis (33 liberal and 15 restrictive). ¶Five patients had missing data and were excluded from this analysis (three liberal and two restrictive). ||One patient had missing data in the liberal group and was excluded from this analysis. **31 patients had missing data and were excluded from this analysis (21 liberal and ten restrictive). † †295 patients had missing data and were excluded from this analysis (214 liberal and 81 restrictive). ‡ ‡One patient in the liberal group was missing data and was excluded from this analysis. recommendations at a formal interim analysis for their continued enrolment, and do a prespecifi ed subgroup analysis for ischaemic heart disease. Despite the results of the Barcelona trial, 14 we would also enrol patients with liver cirrhosis because of the limitations of external validity in that trial. For the interventions, we plan to lower thresholds for transfusion to a haemoglobin concentration of 90 g/L in the liberal arm and to 70 g/L in the restrictive arm, which accounts for the uncertainty in present practice. Although previous transfusion strategy trials have used haemoglobin concentration as an entry criterion, 5, 6, 8, 14 we designed this trial to assess the eff ect of implementation of a treatment policy on a hospital-wide scale for all patients presenting with acute upper gastrointestinal bleeding, and would repeat this effi cient design for a phase 3 trial, but additionally incorporate a prespecifi ed secondary analysis of clinical outcomes using the transfusion threshold in the liberal group as a cutoff . The primary outcome for the phase 3 trial would be mortality. Our estimate of the intracluster correlation coeffi cient, essential for sample size calculation, was similar to that estimated from a UK audit of acute upper gastrointestinal bleeding, 27 which probably shows that both studies were pragmatic, recording all presentations with acute upper gastrointestinal bleeding. We would still randomly allocate by cluster to assess the treatment eff ect of a policy in a diverse patient population in routine clinical care, while minimising contamination. These benefi ts far outweigh the often-cited limitation of statistical ineffi ciency in cluster randomised trials, particularly since suffi cient recruitment would not be a barrier in this trial; we estimate that although 15% more participants would need to be recruited through cluster randomisation than through individual randomisation, recruitment time would be almost 40% less, resulting in a more effi cient trial design (appendix p 5). We believe that this design off ers an attractive method of comparative eff ectiveness research in the NHS for treatment policies that are within the boundaries of normal care and that have clinical equipoise.
EQ-5D † †
Patient consent for routine clinical data collection and telephone follow-up was lower than we expected. For the phase 3 trial, we would seek a consent waiver to enable analysis of routinely recorded inhospital data for all patients. The trial design would be more effi cient through linkage to routine administrative data to record mortality and readmissions, which would allow follow-up for longer periods than would be possible without this data. Telephone follow-up at day 28 for patient-reported outcomes would be replaced by assessment of functional status at discharge to reduce attrition rates due to diffi culties with telephone contact.
Reduction of RBC transfusion for acute upper gastrointestinal bleeding would have substantial fi nancial implications for health-care agencies. In 2013-14, 1·7 million units of RBCs were issued in England, with an estimated 204 000 units for acute upper gastrointestinal bleeding alone, costing UK£123·31 per unit. 32 A 13% reduction, as shown in this trial, would lead to annual savings to the NHS of about £3·3 million for the blood alone, which excludes blood transfusion laboratory and blood administration costs.
We used a pragmatic cluster randomised design to show the feasibility of implementation of hospital-wide transfusion policies for acute upper gastrointestinal bleeding, resulting in a non-signifi cant reduction in blood use and separation in haemoglobin concentration. A large, cluster randomised phase 3 trial to assess the eff ectiveness of transfusion strategies for acute upper gastrointestinal bleeding is now essential before practice guidelines are changed to recommend restrictive transfusion for all patients with acute upper gastrointestinal bleeding.
Panel: Research in context
Systematic review
We did a Cochrane review of randomised controlled trials comparing red blood cell (RBC) transfusion strategies for acute upper gastrointestinal bleeding in 2008, and updated it in 2010. 22 We identifi ed three underpowered trials of 93 participants. [23] [24] [25] The small numbers of participants, missing data, and methodological defi ciencies did not allow meaningful conclusions, justifying the need for a trial of transfusion strategies for acute upper gastrointestinal bleeding. We have identifi ed one single-centre trial from Barcelona, 14 which started in 2003 and had the report published in 2013, halfway through TRIGGER recruitment. Investigators of this trial reported a reduction in mortality and rebleeding with restrictive transfusion and thus recommended restrictive transfusion for acute upper gastrointestinal bleeding. The population in this trial diff ered from ours because a third of participants had liver cirrhosis for which the mechanism of bleeding diff ers and the investigators excluded patients with cardiovascular comorbidity and used care processes unlikely to be generalisable to most health-care institutions. 3
Interpretation
In our trial, the randomised transfusion policies were successfully implemented on a hospital-wide scale across diff erent specialty groups and clinical areas for 6 months, with a high level of protocol adherence, leading to a non-signifi cant reduction in RBC exposure in the restrictive policy and separation in haemoglobin concentration between treatment groups. We did not note any signifi cant diff erences in clinical outcomes, although the trial was not powered for these outcomes. If restrictive transfusion is proven to be safe and eff ective in a large, similarly pragmatic trial, this trial would have the potential to safely reduce use of RBCs for the largest single indication for transfusion in England, and might have broad implications for restrictive use of RBCs after acute haemorrhage. A large cluster randomised trial is feasible and essential to do before clinical practice guidelines recommend restrictive transfusion for all patients with acute upper gastrointestinal bleeding.
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